Zealand Pharma (ZEAL) Stock Price, Fundamentals & Analysis

What ZEAL does

Zealand Pharma (ZEAL) is a biotechnology company that discovers, develops, and commercialises peptide-based medicines. It focuses on gastrointestinal and metabolic diseases, as well as other specialty areas with unmet medical needs. Its product portfolio includes Zegalogue, a single-use syringe or autoinjector for severe hypoglycaemia, and Dasiglucagon bi-hormone artificial pancreas systems that combine insulin and dasiglucagon. The company is also developing Dasiglucagon for congenital hyperinsulinism and glepaglutide, a long-acting GLP-2 analog in Phase III clinical trials for short bowel syndrome. Zealand Pharma (ZEAL) is listed on the Nasdaq Copenhagen and is part of the OMXC25.

Key numbers explained

• The current price is 272,7 DKK, with a -1,16% change today.
• The trailing P/E ratio of 7 compares the share price to the last 12 months of earnings; a lower number can suggest the stock is priced low relative to recent earnings.
• The forward P/E ratio of 36,4 uses expected future earnings, reflecting higher growth expectations than the trailing figure.
• Dividend yield is 0%, and 0% of earnings are paid out as dividends, meaning the company retains all earnings for reinvestment.
• Beta of 0,59 suggests the stock is less volatile than the overall market.
• The 52-week price range is 233,5 – 556, and the price change over the last 52 weeks is -39,6%.
• Revenue for the trailing 12 months is 4,64 mld. DKK, with a year-over-year growth of -50,6%.
• Profit margin of 59% and operating margin of 85,9% indicate strong profitability relative to revenue.
• Return on equity of 16,3% shows how effectively the company generates profit from shareholders' equity.
• Debt-to-equity ratio of 2,3 indicates the company uses more debt than equity to finance its assets.
• Price to book of 1,05 compares the market value to the book value of its assets.

What to watch

Investors tracking Zealand Pharma (ZEAL) may monitor pipeline progress, particularly the Phase III trials for glepaglutide and the development of Dasiglucagon. Regulatory decisions and clinical trial results can significantly impact biotechnology stocks. The company's revenue trend, which has declined -50,6% year over year, is another factor to observe. As a component of the OMXC25, its performance may be influenced by broader Danish market movements. Peer companies like Coloplast (COLO-B) and Novo Nordisk (NOVO-B) operate in related healthcare spaces and may provide context for sector trends. The next earnings date is 12 nov. 2026.